Wearable Devices to Expand AI-Powered Bio-Signal Intelligence with LMM for Health Monitoring Potential Uses
Wearable Devices (Nasdaq: WLDS) announced the expansion of its Large Motor Unit Action Potential Model (LMM) into predictive health monitoring and cognitive state analytics markets. This AI-powered bio-signal platform, previously focused on gesture control in XR, will now analyze muscle activity signals from the wrist for health monitoring applications.
Unlike traditional bio-sensors, LMM continuously learns and adapts, transforming muscle activity data into actionable insights. The technology is being tested for:
- Predictive health monitoring to detect early signs of health conditions
- Cognitive state analytics for monitoring focus, fatigue, and stress levels
- Predictive analytics for user behavior
The company plans to make LMM available to enterprises, researchers, and developers for developing healthcare and sports applications, integrating physiological insights into enterprise solutions, and refining predictive health models. Wearable Devices aims to accelerate commercialization and strategic partnerships across the health sector.
Wearable Devices (Nasdaq: WLDS) ha annunciato l'espansione del suo Modello di Potenziale d'Azione delle Grandi Unità Motorie (LMM) nei mercati del monitoraggio della salute predittivo e dell'analisi dello stato cognitivo. Questa piattaforma bio-signal alimentata dall'IA, precedentemente focalizzata sul controllo gestuale in XR, analizzerà ora i segnali di attività muscolare dal polso per applicazioni di monitoraggio della salute.
Rispetto ai bio-sensori tradizionali, il LMM apprende e si adatta continuamente, trasformando i dati sull'attività muscolare in informazioni utilizzabili. La tecnologia è attualmente in fase di test per:
- Monitoraggio della salute predittivo per rilevare segni precoci di condizioni di salute
- Analisi dello stato cognitivo per monitorare attenzione, affaticamento e livelli di stress
- Analisi predittiva per il comportamento degli utenti
L'azienda prevede di rendere il LMM disponibile a imprese, ricercatori e sviluppatori per sviluppare applicazioni sanitarie e sportive, integrando intuizioni fisiologiche nelle soluzioni aziendali e perfezionando i modelli di salute predittiva. Wearable Devices mira ad accelerare la commercializzazione e le partnership strategiche nel settore della salute.
Wearable Devices (Nasdaq: WLDS) anunció la expansión de su Modelo de Potencial de Acción de Grandes Unidades Motoras (LMM) en los mercados de monitoreo de salud predictivo y análisis del estado cognitivo. Esta plataforma de bio-señales impulsada por IA, que anteriormente se centraba en el control por gestos en XR, ahora analizará las señales de actividad muscular de la muñeca para aplicaciones de monitoreo de salud.
A diferencia de los bio-sensores tradicionales, el LMM aprende y se adapta continuamente, transformando los datos de actividad muscular en información útil. La tecnología se está probando para:
- Monitoreo de salud predictivo para detectar signos tempranos de condiciones de salud
- Análisis del estado cognitivo para monitorear la atención, la fatiga y los niveles de estrés
- Análisis predictivo del comportamiento del usuario
La empresa planea hacer que el LMM esté disponible para empresas, investigadores y desarrolladores para desarrollar aplicaciones de salud y deportes, integrando conocimientos fisiológicos en soluciones empresariales y perfeccionando modelos de salud predictiva. Wearable Devices busca acelerar la comercialización y las asociaciones estratégicas en el sector salud.
웨어러블 디바이스 (Nasdaq: WLDS)는 대형 운동 단위 행동 잠재력 모델 (LMM)을 예측 건강 모니터링 및 인지 상태 분석 시장으로 확장한다고 발표했습니다. 이전에 XR에서 제스처 제어에 초점을 맞췄던 이 AI 기반 생체 신호 플랫폼은 이제 건강 모니터링 애플리케이션을 위해 손목에서 근육 활동 신호를 분석할 것입니다.
전통적인 생체 센서와 달리 LMM은 지속적으로 학습하고 적응하여 근육 활동 데이터를 실행 가능한 통찰력으로 변환합니다. 이 기술은 다음을 위해 테스트되고 있습니다:
- 건강 상태의 조기 징후를 감지하기 위한 예측 건강 모니터링
- 집중력, 피로 및 스트레스 수준을 모니터링하기 위한 인지 상태 분석
- 사용자 행동에 대한 예측 분석
회사는 LMM을 기업, 연구자 및 개발자에게 제공하여 헬스케어 및 스포츠 애플리케이션을 개발하고, 생리학적 통찰력을 기업 솔루션에 통합하며, 예측 건강 모델을 개선할 계획입니다. 웨어러블 디바이스는 건강 분야에서 상용화 및 전략적 파트너십을 가속화하는 것을 목표로 하고 있습니다.
Wearable Devices (Nasdaq: WLDS) a annoncé l'expansion de son Modèle de Potentiel d'Action des Grandes Unités Motrices (LMM) dans les marchés de la surveillance de la santé prédictive et de l'analyse de l'état cognitif. Cette plateforme de bio-signaux alimentée par l'IA, qui était auparavant axée sur le contrôle gestuel en XR, analysera désormais les signaux d'activité musculaire du poignet pour des applications de surveillance de la santé.
Contrairement aux bio-capteurs traditionnels, le LMM apprend et s'adapte en continu, transformant les données d'activité musculaire en informations exploitables. La technologie est en cours de test pour:
- Surveillance de la santé prédictive pour détecter les signes précoces de problèmes de santé
- Analyse de l'état cognitif pour surveiller la concentration, la fatigue et les niveaux de stress
- Analyse prédictive du comportement des utilisateurs
L'entreprise prévoit de rendre le LMM disponible aux entreprises, chercheurs et développeurs pour développer des applications de santé et de sport, intégrer des connaissances physiologiques dans des solutions d'entreprise et affiner les modèles de santé prédictive. Wearable Devices vise à accélérer la commercialisation et les partenariats stratégiques dans le secteur de la santé.
Wearable Devices (Nasdaq: WLDS) hat die Erweiterung seines Modells für Aktionspotentiale großer motorischer Einheiten (LMM) in die Märkte für prädiktive Gesundheitsüberwachung und kognitive Zustandsanalytik angekündigt. Diese KI-gestützte Bio-Signal-Plattform, die zuvor auf Gestensteuerung in XR fokussiert war, wird jetzt Muskelaktivitätssignale vom Handgelenk für Anwendungen zur Gesundheitsüberwachung analysieren.
Im Gegensatz zu herkömmlichen Bio-Sensoren lernt und passt sich das LMM kontinuierlich an und verwandelt Daten zur Muskelaktivität in umsetzbare Erkenntnisse. Die Technologie wird getestet für:
- Prädiktive Gesundheitsüberwachung zur Erkennung früher Anzeichen von Gesundheitszuständen
- Kognitive Zustandsanalytik zur Überwachung von Konzentration, Müdigkeit und Stresslevel
- Prädiktive Analytik für das Nutzerverhalten
Das Unternehmen plant, das LMM Unternehmen, Forschern und Entwicklern zur Verfügung zu stellen, um Gesundheits- und Sportanwendungen zu entwickeln, physiologische Erkenntnisse in Unternehmenslösungen zu integrieren und prädiktive Gesundheitsmodelle zu verfeinern. Wearable Devices zielt darauf ab, die Kommerzialisierung und strategische Partnerschaften im Gesundheitssektor zu beschleunigen.
- Expansion into new healthcare markets broadens revenue potential
- Development of continuous learning AI technology demonstrates technological advancement
- Strategic move to open platform to enterprises and developers could accelerate adoption
- Potential for multiple revenue streams through partnerships in health sector
- Technology still in evaluation phase with no immediate revenue impact
- No concrete timeline for commercial deployment provided
- No existing partnerships or contracts announced
- Uncertain market adoption and competition in healthcare monitoring space
Insights
Wearable Devices' announcement represents a strategic expansion of their AI-powered bio-signal platform (LMM) beyond gesture controls into predictive health monitoring and cognitive state analytics. This move positions the company to potentially capture value in the growing digital health monitoring sector.
The technology's differentiation lies in its approach to continuous learning and adaptation of muscle activity signals, rather than passive data collection typical of most wearables. By analyzing micro-movements and muscle tone patterns, LMM could theoretically detect subtle physiological changes that precede visible symptoms.
However, several critical factors temper enthusiasm. The announcement lacks specifics on: clinical validation studies, regulatory pathway considerations, accuracy metrics, or established healthcare partnerships. The repeated qualifiers ("potential markets," "being evaluated," "intending to," "aims to") indicate this remains in early experimental stages rather than near-term commercialization.
The B2B platform strategy could accelerate adoption if successful, but healthcare integration requires substantial validation and typically moves at a deliberate pace. Without demonstrated clinical utility or regulatory clarity, this represents a directional shift with uncertain commercial timeline rather than an imminent market entry.
This announcement reflects Wearable Devices' attempt to expand their addressable market by applying their proprietary LMM technology to health monitoring applications. The strategic significance lies in their transition from purely interface-focused applications (XR control) to physiological analytics with potential recurring revenue models.
The technical approach leverages the same fundamental technology (muscle activity signal processing) but applies different analytical frameworks to extract health-relevant insights. This represents efficient R&D utilization but faces significant challenges in the health domain:
- No mention of training data size/quality specific to health applications
- Absence of validation studies or accuracy metrics
- No disclosed integration pathways with existing health platforms
The B2B platform strategy (making LMM available to enterprises/developers) suggests Wearable is positioning itself as infrastructure rather than end-solution provider. This could accelerate use-case discovery but may dilute revenue capture compared to vertical integration approaches.
While conceptually promising, the announcement lacks concrete partnership announcements, implementation timelines, or revenue projections - indicating early exploration rather than imminent commercialization. The technology's competitive advantage versus established health wearables from Apple, Fitbit and medical device companies remains unproven.
Yokneam Illit, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced the expansion of its Large Motor Unit Action Potential Model (“LMM”) into new potential markets, such as predictive health monitoring and cognitive state analytics. This development will enable the broadening of bio-signal intelligence applications beyond wearables and will offer businesses and healthcare providers access to real-time physiological insights for monitoring health and wellness conditions.
This announcement follows Wearable Devices’ recent introduction of LMM as a groundbreaking AI-driven bio-signal platform focused on gesture-based control in extended reality (“XR”) and neural interaction with digital devices. The Company’s LMM approach to analyzing muscle activity signals will support the expansion into the field of health monitoring, enabling users to enhance their performance across various domains.
From Passive Monitoring to Proactive Intelligence
Unlike traditional bio-sensors that collect data passively, LMM continuously learns and adapts, turning muscle activity signals from the wrist into actionable insights. The technology is now being evaluated in controlled environments for real-world applications, including:
- Predictive Health Monitoring - Detecting hidden patterns in muscle activity that may indicate early signs of health conditions before symptoms appear, revolutionizing preventive diagnostics and digital health tracking.
- Cognitive State & Performance Analytics - Monitoring focus, fatigue, and stress levels through muscle tone and micro-movements, optimizing work productivity and mental well-being.
- Exploring Predictive Analytics - Assessing whether continuous monitoring of neural data can improve AI-driven user behavior predictions.
A Platform for Innovation: Opening LMM to Business Partners
Recognizing the transformative potential of bio-signal intelligence, Wearable Devices is intending to make LMM available to enterprises, researchers, and developers. The Company’s AI-powered bio-signal data platform is expected to enable businesses to:
- Develop custom applications tailored to healthcare and sports for athletic performance optimization.
- Integrate real-time physiological insights into enterprise solutions to enhance safety, performance, and productivity.
- Leverage LMM’s AI engine to continuously refine predictive health and interaction models.
Following the initial evaluation phase, Wearable Devices aims to accelerate commercialization and strategic partnerships across the health sector, reinforcing its position as a pioneer in bio-signal intelligence and neural interface technology.
“We believe LMM represents the next leap in bio-signal intelligence,” said Guy Wagner, President and Chief Scientific Officer of Wearable Devices. “Beyond XR and wearable computing, LMMs will allow us to enter markets that need real-time physiological insights - helping businesses, AI based health platforms, and healthcare providers to gain insights that will transform and personalize their services at scale.”
About Wearable Devices Ltd.
Wearable Devices Ltd. is a pioneering growth company revolutionizing human-computer interaction through its AI-powered neural input technology for both consumer and business markets. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company’s innovative products, including the Mudra Band for iOS and Mudra Link for Android, enable seamless, touch-free interaction by transforming subtle finger and wrist movements into intuitive controls. These groundbreaking solutions enhance gaming, and the rapidly expanding AR/VR/XR landscapes. The Company offers a dual-channel business model: direct-to-consumer sales and enterprise licensing. Its flagship Mudra Band integrates functional and stylish design with cutting-edge AI to empower consumers, while its enterprise solutions provide businesses with the tools to deliver immersive and interactive experiences. By setting the input standard for the XR market, Wearable Devices is redefining user experiences and driving innovation in one of the fastest-growing tech sectors. Wearable Devices’ ordinary shares and warrants trade on the Nasdaq under the symbols “WLDS” and “WLDSW,” respectively.
Forward-Looking Statements Disclaimer
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, we are using forward-looking statements when we discuss the benefits and advantages of our devices and technology, including the potential of LMMs, the potential to accelerate commercialization and strategic partnerships across the health sector, and entering markets that need real-time physiological insights. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the trading of our ordinary shares or warrants and the development of a liquid trading market; our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2024, filed on March 20, 2025 and our other filings with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contact
Michal Efraty
IR@wearabledevices.co.il
FAQ
What new markets is Wearable Devices (WLDS) expanding its LMM technology into?
How does Wearable Devices' LMM technology differ from traditional bio-sensors?
What are the main applications being tested for WLDS's LMM technology in 2025?
How will Wearable Devices (WLDS) commercialize its LMM platform?
